Literature DB >> 33713739

Endogenous retrovirus expression activates type-I interferon signaling in an experimental mouse model of mesothelioma development.

Suna Sun1, Francesca Frontini1, Weihong Qi2, Ananya Hariharan1, Manuel Ronner1, Martin Wipplinger1, Christophe Blanquart3, Hubert Rehrauer2, Jean-François Fonteneau3, Emanuela Felley-Bosco4.   

Abstract

Early events in an experimental model of mesothelioma development include increased levels of editing in double-stranded RNA (dsRNA). We hypothesised that expression of endogenous retroviruses (ERV) contributes to dsRNA formation and type-I interferon signaling. ERV and interferon stimulated genes (ISGs) expression were significantly higher in tumor compared to non-tumor samples. 12 tumor specific ERV ("MesoERV1-12") were identified and verified by qPCR in mouse tissues. "MesoERV1-12" expression was lower in mouse embryonic fibroblasts (MEF) compared to mesothelioma cells. "MesoERV1-12" levels were significantly increased by demethylating agent 5-Aza-2'-deoxycytidine treatment and were accompanied by increased levels of dsRNA and ISGs. Basal ISGs expression was higher in mesothelioma cells compared to MEF and was significantly decreased by JAK inhibitor Ruxolitinib, by blocking Ifnar1 and by silencing Mavs. "MesoERV7" promoter was demethylated in asbestos-exposed compared to sham mice tissue as well as in mesothelioma cells and MEF upon 5-Aza-CdR treatment. These observations uncover novel aspects of asbestos-induced mesothelioma whereby ERV expression increases due to promoter demethylation and is paralleled by increased levels of dsRNA and activation of type-I IFN signaling. These features are important for early diagnosis and therapy.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Endogenous retrovirus; Mesothelioma; Type-I interferon Signaling

Year:  2021        PMID: 33713739     DOI: 10.1016/j.canlet.2021.03.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  Editorial: Understanding the Interplay Between the Tumor Immune Microenvironment and Genetic Alterations in Thoracic Malignancies.

Authors:  Giulia Pasello; Jordi Remon; Emanuela Felley-Bosco
Journal:  Front Oncol       Date:  2022-03-10       Impact factor: 6.244

2.  Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype.

Authors:  Rebecca L Porter; Siyu Sun; Micayla N Flores; Emily Berzolla; Eunae You; Ildiko E Phillips; Neelima Kc; Niyati Desai; Eric C Tai; Annamaria Szabolcs; Evan R Lang; Amaya Pankaj; Michael J Raabe; Vishal Thapar; Katherine H Xu; Linda T Nieman; Daniel C Rabe; David L Kolin; Elizabeth H Stover; David Pepin; Shannon L Stott; Vikram Deshpande; Joyce F Liu; Alexander Solovyov; Ursula A Matulonis; Benjamin D Greenbaum; David T Ting
Journal:  J Clin Invest       Date:  2022-08-15       Impact factor: 19.456

Review 3.  Endogenous Retroviruses (ERVs): Does RLR (RIG-I-Like Receptors)-MAVS Pathway Directly Control Senescence and Aging as a Consequence of ERV De-Repression?

Authors:  Eros Di Giorgio; Luigi E Xodo
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

Review 4.  Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy.

Authors:  Marion Grard; Camille Chatelain; Tiphaine Delaunay; Elvire Pons-Tostivint; Jaafar Bennouna; Jean-François Fonteneau
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

5.  Double-Stranded RNA Structural Elements Holding the Key to Translational Regulation in Cancer: The Case of Editing in RNA-Binding Motif Protein 8A.

Authors:  Asra Abukar; Martin Wipplinger; Ananya Hariharan; Suna Sun; Manuel Ronner; Marika Sculco; Agata Okonska; Jelena Kresoja-Rakic; Hubert Rehrauer; Weihong Qi; Victor W van Beusechem; Emanuela Felley-Bosco
Journal:  Cells       Date:  2021-12-15       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.